Technical Analysis for NGEN - Nervgen Pharma Corp
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Crossed Above 20 DMA | Bullish | 2.77% | |
| Crossed Above 50 DMA | Bullish | 2.77% | |
| 180 Bullish Setup | Bullish Swing Setup | 2.77% | |
| Wide Bands | Range Expansion | 2.77% | |
| 180 Bearish Setup | Bearish Swing Setup | 16.07% | |
| Calm After Storm | Range Contraction | 16.07% | |
| NR7 | Range Contraction | 16.07% | |
| NR7-2 | Range Contraction | 16.07% |
| Alert | Time |
|---|---|
| Up 1 ATR | 1 day ago |
| Up 5% | 1 day ago |
| Up 3% | 1 day ago |
| Bullish 180 Entry | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-11-07
NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of nerve damage. Its product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University of Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.98 |
| 52 Week Low | 1.58 |
| Average Volume | 44,093 |
| 200-Day Moving Average | 2.562 |
| 50-Day Moving Average | 2.477 |
| 20-Day Moving Average | 2.464 |
| 10-Day Moving Average | 2.426 |
| Average True Range | 0.172 |
| RSI (14) | 55.16 |
| ADX | 18.92 |
| +DI | 37.989 |
| -DI | 23.109 |
| Chandelier Exit (Long, 3 ATRs) | 2.284 |
| Chandelier Exit (Short, 3 ATRs) | 2.566 |
| Upper Bollinger Bands | 2.823 |
| Lower Bollinger Band | 2.106 |
| Percent B (%b) | 0.69 |
| BandWidth | 29.099 |
| MACD Line | -0.021 |
| MACD Signal Line | -0.024 |
| MACD Histogram | 0.0032 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.930 | ||||
| Resistance 3 (R3) | 2.933 | 2.827 | 2.875 | ||
| Resistance 2 (R2) | 2.827 | 2.743 | 2.825 | 2.857 | |
| Resistance 1 (R1) | 2.713 | 2.691 | 2.770 | 2.710 | 2.838 |
| Pivot Point | 2.607 | 2.607 | 2.635 | 2.605 | 2.607 |
| Support 1 (S1) | 2.493 | 2.523 | 2.550 | 2.490 | 2.362 |
| Support 2 (S2) | 2.387 | 2.471 | 2.385 | 2.343 | |
| Support 3 (S3) | 2.273 | 2.387 | 2.325 | ||
| Support 4 (S4) | 2.270 |
